How do you choose between axicabtagene ciloleucel and tisagenlecleucel in patients with follicular lymphoma for whom you are recommending CAR T-cell therapy?  

This is an area of uncertainty. There are no head-to-head data to bring to bear, of course (and, if there were, you probably wouldn’t need to ask). The toxicity profile of the two cells is clearly different, with lower rates of severe toxicity with tisacel than with axicel. As neither product ...

That is also challenging. I prefer axi-cel as I have more experience with it. I reserve tisa-cel for older patients or those with comorbidities. However, they both work very well.